

Cancer Immunotherapies – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -

<https://marketpublishers.com/r/CAFC5DBB4608EN.html>

Date: August 2026

Pages: 0

Price: US\$ 3,400.00 (Single User License)

ID: CAFC5DBB4608EN

Contents

CANCER IMMUNOTHERAPIES

- The “Cancer Immunotherapies – Pipeline Insights 2018” report covers an in-depth analysis of Cancer Immunotherapies drug molecules currently undergoing clinical studies.
- It provides a deep understanding of potential Cancer Immunotherapies drug molecules across all drug development phases.
- The report assesses the pipeline Cancer Immunotherapies molecules by stage of development (discovery, pre-clinical, IND, Phase I, Phase II, Phase III and pre-registration), by recruitment status (recruiting, active not recruiting, completed, NA, and unknown), therapy type (monotherapy, combination products) molecule type (small molecules, biologics) and route of administration (oral, IV, and others).
- The report provides a snapshot of discontinued and dormant drugs too. In addition, the report includes key insights on other development activities, including (but not limited to) – licensing, collaborations, acquisitions, funding, patent, and regulatory designations.
- The report covers company profiles key players in developing Cancer Immunotherapies drug molecules. The company profile includes key info on overview, financial highlights, product portfolio, business strategies, and key recent developments.

MARKET OUTLOOK

- Cancer is a group of diseases that are characterized by abnormal cell growth. It involves a multi-step process because a single mutation is almost certainly not sufficient to become a malignant cell.
- Some cellular processes are deregulated that will allow the cells to proliferate unancontrollably while avoiding apoptosis. Initially, key cell growth, pro-apoptotic and proliferative signaling pathways are deregulated in most of the cancers.

- These signaling pathways lead to cell survival, continued proliferation and the avoidance of programmed cell death.
- The diseases are caused by the accumulation of genetic mutations that provide selective advantages allowing cells to evolve and accumulate virtually in all sites and tissues of the human body.
- Immunotherapy of cancer is a type of cancer treatment that stimulates the human bodies natural immune system to fight against the malignant cells. This therapy is introduced to the cancer patients to stop the spread of cancer, to decline the growth of cancer cells and to boosts the natural immunity for destroying the cancer cells.
- The introduction of advanced treatment options in cancer immunotherapy that are more effective and efficient are resulting in rising R&D. The shift of therapies from traditional chemotherapies to immunotherapies is prompting the overall market.
- However, the demand in the market is augmented by more significant factors. For example, the launch of more effective bioinformatics tools and rise in the requirement of cancer monoclonal antibodies that offers improved drug development options will help with more demand for cancer immunotherapy. Further, the surge in providing immunotherapy therapeutics compared to conventional ones and a high number of cancer incidences could increase market growth in the coming years.

WHAT'S TRENDING IN THIS MARKET?

- Cancer immunotherapies are targeted for treating several types of cancer including Lung cancer, Breast cancer, Colorectal cancer, Melanoma cancer, Prostate cancer, Head & Neck cancer, melanoma, NSCLC, and ovarian cancer. Cancer immunotherapies use to treat these cancers by using the products including antibody drug conjugates (ADCs), cytokines, bispecific monoclonal antibodies, interferons, PD-1/PD-L1 inhibitors, chimeric antigen receptor (CAR) T-Cell Therapy, dendritic cells, IDO inhibitors and adopted cell therapy (ACT).
- The market size for cancer immunotherapies is known to grow at an increasing rate over the forecast period. Overall, there are 2,037 products found to be in active development in the pipeline of cancer immunotherapy.
- This makes a significant portion of the entire oncology pipeline and adds a strong interest in product development in this class of therapy.
- This is because of the growing clinical rationale besides developing such therapies, and the interest of drug developers to invest in developing novel therapeutics, which will offer appropriate product differentiation from competitors of the market.
- Anyway, the cancer immunotherapy pipeline is found to be clearly strong; a notable proportion is made up by early-stage products, those from the discovery stage to phase I.
- This indicates the difficulty that is associated with progressing cancer immunotherapies from the preclinical laboratory to clinical application studies in

humans. Immunotherapies found to have fewer side effects and thus hold high efficacy to treat various cancers. Cancer immunotherapies have made nearly 50% of the cancer drugs in the market.

- Development of targeted and combination therapies was trending now in the market for treating cancers. As the patent expiry of top-selling drugs in the market is taking place, thus it places a challenge for the development of novel drug therapeutics in cancer patients.
- The interest in cancer immunotherapy development has been driven by an increase in demand for cancer monoclonal antibodies and by the increased understanding of the immune system that acts as a hallmark of cancer pathophysiology, importantly immune evasion of developing cancer cells.

SCOPE OF THE REPORT

- Provides comprehensive understanding of active Cancer Immunotherapies pipeline drug candidates
- Includes all-inclusive pipeline product coverage with segregation by various stages of the pipeline from discovery to late-stage.
- Offers pipeline assessment by monotherapy, combination therapy products, and route of administration
- Provides a comparative analysis of key marketed products and pipeline drug candidates
- Includes detailed pipeline drug profiles covering – product description, chemical information, molecule type, mechanism of action, route of administration, product safety and efficacy, developers and collaborators
- Provides key info on players involved in clinical R&D of Cancer Immunotherapies drug candidates.
- Provides in-depth coverage of key news related to Cancer Immunotherapies drug molecules, including major mergers and acquisitions and product development updates such as clinical trial progression updates and regulatory updates.

REASONS FOR PURCHASING THIS REPORT?

- To obtain an understanding of the current Cancer Immunotherapies pipeline landscape.
- To determine drug development dynamics and leverage it for innovation of novel or repositioned drugs.
- To valuably optimize R&D activities in-line with robust therapeutic drug markets.
- To devise strategic initiatives by identifying prospective partners with progressing projects.

Cancer Immunotherapies – Pipeline Insight, 2018

I would like to order

Product name: Cancer Immunotherapies – Pipeline Insights – 2018 Size, Share, Industry, Forecast and outlook (2024-2031) Market -

Product link: <https://marketpublishers.com/r/CAFC5DBB4608EN.html>

Price: US\$ 3,400.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/CAFC5DBB4608EN.html>